Animal Biotechnology Market Growth Accelerated by Developing New Therapies
Animal biotechnology involves genetic engineering and gene
manipulation techniques to develop livestock with desirable traits and produce
specialized pharmaceutical or industrial products from animals.
Biopharmaceuticals produced using animal biotechnology are effectively utilized
for treating human diseases.
The global Animal Biotechnology Market is estimated to be
valued at US$ 27.39 Bn in 2024 and is expected to exhibit a CAGR of 8.9% over the forecast period
2024 to 2031, as highlighted in a new report published by Coherent Market
Insights.
Market key trends:
Developing New Therapies
One of the key trends driving growth in the global
animal biotechnology market size is increasing research into developing
new cell and gene therapies. Numerous companies are conducting clinical trials
aimed at developing genetically engineered animal organs and tissues for
transplant into humans. Such therapies hold potential to address the shortage
of organ donors. Additionally, animal biotechnology is being leveraged to
develop new vaccines and therapies for various animal diseases. Advancements in
cloning and genetic engineering techniques are increasing success rates of
developing customized biologic products from transgenic livestock and producing
monoclonal antibodies in the milk of transgenic animals.
Segment Analysis
The global animal biotechnology market is dominated by transgenic animal
sub-segment. Transgenic animals accounted for more than 35% of the market share
in 2024 owing to increasing use of transgenic technology for the development of
genetically modified livestock and animals used in research. Transgenic animals
are genetically engineered to include new genes which help researchers
understand the function of genes as well as produce new genetically modified
animal breeds in livestock with improved traits and pharmaceutical products in
their milk.
Key Takeaways
The global animal biotechnology market is expected to
witness high growth over the forecast period of 2024 to 2031 supported by
increasing meat consumption worldwide.
Regional analysis: The North American region dominated the
global animal biotechnology market in 2024 with more than 30% share owing to
major biotech companies being based out of the US and growing adoption of
biotech-based animal products in the region. Furthermore, rising agriculture
and livestock sector, and increasing funding for biotechnology research and
development by government organizations is also fueling the growth of the
animal biotechnology market in North America.
Key players operating in the global animal biotechnology
market are Heska Corporation, Indian Immunologicals Ltd., HESTER BIOSCIENCES
LIMITED, Zoetis Inc., Boehringer Ingelheim International GmbH, Biogénesis Bagó,
Merck & Co., Inc., Virbac, Elanco, Cadila Pharma, Thermo Fisher Scientific
Inc., Idexx Laboratories, Randox Laboratories Ltd., Gold Standard Diagnostics.,
Bionote USA Inc., Meiji Holdings Co., Ltd., Kemin Industries, Inc., and Pfizer
Inc. Major players are focusing on new product launches, acquisitions, and
geographical expansion to increase their market share in the lucrative animal
biotechnology market.
Explore
Our More Blogs Here: https://www.ukwebwire.com/the-global-animal-biotechnology-market-is-driven-by-advancements-in-animal-healthcare/
Explore
more trending article on this topic: https://masstamilan.tv/understanding-construction-aggregates/
Comments
Post a Comment